Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.

@article{Robinson1990ClinicalEO,
  title={Clinical effects of the 5-HT1A partial agonists in depression: a composite analysis of buspirone in the treatment of depression.},
  author={Diane S Robinson and Karl E. Rickels and John P. Feighner and Louis F Fabre and Richard E. Gammans and R. C. Shrotriya and D R Alms and Jim Andary and M E Messina},
  journal={Journal of clinical psychopharmacology},
  year={1990},
  volume={10 3 Suppl},
  pages={67S-76S}
}
The azapirone class of anxiolytic drugs is being evaluated for clinical use in the treatment of depression. Buspirone, a serotonin (5-hydroxytryptamine, 5-HT) partial agonist active at the 5-HT1A receptor subtype, was evaluated in the treatment of depression in a series of five placebo-controlled, parallel group studies involving 382 patients with DSM-III major depression and significant associated anxiety symptoms (both Hamilton depression [HAM-D] and Hamilton anxiety [HAM-A] scales greater… CONTINUE READING
43 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…